GW0742
GW0742 (GW610742): Pioneering PPARδ/β Agonist[edit | edit source]
GW0742, also recognized under its developmental code name GW610742, is a molecular compound which specifically targets the PPARδ/β receptor. Heralded as a possible therapeutic intervention for various metabolic disorders, its development and investigation have been primarily undertaken by the pharmaceutical giant, GlaxoSmithKline.
Background and Synthesis[edit | edit source]
PPARs, or Peroxisome Proliferator-Activated Receptors, play a fundamental role in regulating lipid and glucose metabolism. Among the PPAR subtypes, PPARδ/β is implicated in diverse biological processes, including fat burning, insulin sensitivity, and inflammation. GW0742, as a selective PPARδ/β agonist, represents a targeted approach to modulating these pathways for therapeutic intent[1].
Mechanism of Action[edit | edit source]
The efficacy of GW0742 lies in its ability to bind and activate the PPARδ/β receptor. Once activated, this receptor can induce transcription of specific genes that play roles in lipid and glucose metabolism, inflammation, and other cellular processes. This mechanism suggests that GW0742 can potentially regulate energy balance, lipid levels, and inflammatory responses in the body.
Potential Therapeutic Benefits[edit | edit source]
While exhaustive clinical trials are essential for definitive therapeutic claims, preliminary investigations and studies have hinted at the potential benefits of GW0742:
- Metabolic Syndromes: Given its role in lipid and glucose metabolism, GW0742 could potentially aid in managing conditions characterized by insulin resistance, obesity, and dyslipidemia.
- Anti-inflammatory Properties: Chronic inflammation is a hallmark of several diseases. The drug might serve as a modulator to decrease inflammatory responses.
- Cardiovascular Health: By modulating lipid metabolism, there's a potential for GW0742 to play a role in preventing atherosclerosis and related cardiovascular diseases.
These potential applications offer a glimpse into the broad spectrum of therapeutic areas GW0742 may influence[2].
Research and Development Status[edit | edit source]
GlaxoSmithKline's research division has been at the forefront of investigating GW0742's pharmacological properties and therapeutic potentials. As with all experimental drugs, a rigorous series of clinical trials, toxicity studies, and efficacy assessments are imperative to determine its suitability for market release[3].
Conclusion[edit | edit source]
GW0742, with its selectivity for the PPARδ/β receptor, represents a promising avenue in the realm of targeted metabolic therapies. Its potential impacts on metabolic syndromes, inflammation, and cardiovascular health position it as a compound of significant pharmacological interest. Continuous research and monitoring will determine its eventual position in therapeutic regimens.
See also[edit | edit source]
References[edit | edit source]
- ↑ Oliver, W. R., et al. (2001). A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences, 98(9), 5306-5311.
- ↑ Shearer, B. G., et al. (2008). Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist. Molecular Endocrinology, 22(2), 523-529.
- ↑ GlaxoSmithKline. (2010). Progress report on GW0742 Phase II Clinical Studies. GlaxoSmithKline Research Update.
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
